Why is it so hard for Māori and Pasifika to access weight loss drugs?
Māori and Pasifika communities in New Zealand face significant barriers to accessing GLP-1 weight loss medications like Wegovy. These challenges include high costs, lack of awareness, and systemic healthcare inequalities rooted in historical and socioeconomic factors.
Why it matters
The disparity in access to life-improving medical treatments highlights ongoing health equity issues for indigenous and marginalized populations.
Despite an increased risk of obesity, Māori and Pasifika who have accessed GLP-1 weight loss drugs like Wegovy are a small minority.
The article focuses on systemic inequality and social justice, framing the issue through the lens of colonialism and healthcare access.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in